340B Drug Pricing Program: Rebate Model Considerations

In this episode, Gabriel Scott, Mark Ogunsusi, and Amanda Smith take a focused look at the 340B Drug Pricing Program, with particular attention to recent developments related to proposals for a 340B rebate model. They discuss why stakeholders may support or oppose a rebate ‑ based approach to 340B pricing and highlight key considerations relating to such a model.